Adverse events caused by MRI contrast agents: Implications for radiographers who inject

Radiography

Volumn 18, Issue 2, 2012, Pages 132-136

  Marshall, Gill ^a   Kasap, Chris ^b  

^a UNIVERSITY OF CUMBRIA   (United Kingdom)

^b BURNLEY GENERAL HOSPITAL   (United Kingdom)

Author keywords

Contrast agents; Extended role; Hydration; Nephrogenic systemic fibrosis; Radiographers; Side effects

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE;

ANAPHYLACTIC SHOCK; ANAPHYLAXIS; DIZZINESS; DRUG TOLERABILITY; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MEDICAL PRACTICE; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PRIORITY JOURNAL; RADIOGRAPHY; RADIOLOGY; REVIEW; TASTE DISORDER;

EID: 84859215381     PISSN: 10788174     EISSN: 15322831     Source Type: Journal    
DOI: 10.1016/j.radi.2010.09.007     Document Type: Review

References (55)

1. Roditi G. MRI contrast agent safety in renal impairment. Clinical Risk 2009, 15:47-53.
2. Sales and marketing statement 2006, Schering Healthcare Limited, Burgess Hill.
3. Miles A., Runge V. Contrast agents for MRI safety update. Topics in Magnetic Resonance Imaging 2003, 14(5):426-435.
4. Tweedle M., Eaton S., Eckelman W., Gaughan G.T., Hagan J., Wedeking P.W., et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. Investigative Radiology 1988, 23(1):236-239.
5. Runge V. The safety of MR contrast media: a literature review. Applied Radiology 2001, 12(Suppl.):8-14.
6. Kirchin M., Runge V. Contrast agents for magnetic resonance imaging safety update. Topics in Magnetic Resonance Imaging 2003, 14(5):426-435.
7. Idee J., Port M., Ranal M., Le Greneur S. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundamental and Clinical Pharmacology 2006, 20(6):563-576.
8. Dawson P. Gadolinium chelates: chemistry. Textbook of contrast media 1999, 291-296. ISS Medical Media, Oxford. P. Dawson, D. Cosgriove, R. Grainger (Eds.).
9. Thomsen H., Morcos S., Dawson P. Is there a casual relationship between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?. Clinical Radiology 2006, 61(11):905-906.
10. Hughes J., Jan W., Goodie J., Lund R., Rankin S. MR urography: evaluation of different techniques in non-dilated tracts. Clinical Radiology 2002, 57:989-994.
11. Ten Cate M., Wetzels J. Toxicity of contrast media: an update. Netherland Journal of Medicine 2008, 66:416-422.
12. Stenver D. Pharmacovigilance: what to do if you see an adverse reaction and the consequences. 2008; 66 p. 184-6.
13. Broome D., Girguis M., Baron M. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. American Journal of Roentgenology 2007, 18:586-592.
14. Bellin M., Van Der Molen A. Extra-cellular gadolinium-based contrast media: an overview. European Journal of Radiology 2008, 66:160-167.
15. Laniado M., Weinmann H., Schorner W. First use of Gd-DTPA/dimeglumine in man. Physiological Chemistry and Physics and Medical NMR 1984, 16:157-165.
16. Shellock F., Kanal E. Bioeffects and safety. Magnetic resonance imaging 1999, 291-306. Mosby, St. Louis. D.D. Stark, W.G. Bradley (Eds.).
17. Nelson K., Gilford L., Lauber-Huber C., Gross C., Lasser T. Clinical safety of gadopentetate dimeglumine. Radiology 1995, 196:439-443.
18. Jordan R., Mintz R. Fatal reaction to gadopentetate dimeglumine. American Journal of Roentgenology 1995, 164:743-744.
19. Cowper S., Bucala R., Leboit P. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: setting the record straight. Seminars in Arthritis and Rheumatism 2006, 35:208-210.
20. Gibson S., Farver C., Prayson R. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Archives of Pathology and Laboratory Medicine 2006, 130:209-212.
21. Sadowski E., Bennett L., Chan M., Wentland A., Garret A., Garrett B., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243:148-157.
22. American College of Radiology Manual on contrast media version 6 2008, AmericanCollege of Radiology, New York.
23. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR), [Last accessed 18.06.09]. http://www.icnfdr.org.
24. Markman P., Skov L., Rossen K. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Journal American Society of Nephrology. 2006, 17:2359-2362.
25. Royal College of Radiologists Gadolinium based contrast media and nephrogenic systemic fibrosis 2007, Royal College of Radiologists, London.
26. Thomsen H., Markman P. Extra-cellular GD-CA: differences in prevalence of NSF. European Journal of Radiology 2008, 66(2):180-183.
27. Medicines and Healthcare products Regulatory Authority Gadolinium-containing MRI contrast agents and Nephrogenic Systemic Fibrosis (NSF) Update, [Last accessed 01.06.07]. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2031543%3FssSourceNodeId%3d221.
28. Kanal E., Applegate G., Gillen C. Review of adverse reactions, including anaphylaxis, in 5260 cases receiving Gd-DTPA by bolus injection. Radiology 1990, 177:159.
29. Morcos S., Bellin M., Thomsen H., Almen P., Aspelin G., Heinz-Peer J., et al. Reducing the risk of iodine based and MRI contrast media administration: recommendation of a questionnaire at the time of booking. European Journal of Radiology 2008, 66:225-229.
30. ESUR guidelines on contrast media v 7 2008, [accessed 25.03.10]. http://www.esur.org/ESURguidelines23.0html.
31. Brugieres P., Gaston A., Degryse H., Parizel P., Schepper A., Berry I., et al. Randomised double-blind trial of the safety and efficiency of two gadolinium complexes (Gd-DTPA/DOTA). Neuroradiology 1994, 36:27-30.
32. Olukotun A., Parker J., Meeks M., Lucas M.A., Fowler D., Lucas T. Safety of gadoteridol injection: the US clinical trial experience. Journal of Magnetic Resonance Imaging 1995, 5:17-25.
33. Sze G., Brant-Zawadzki M., Haughton V., Maravilla K., McNamara T., Kumar A., et al. Multi-centre study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991, 76:513-518.
34. Ekholm S., Jonsson E., Sandvik L., Fagerlund M., Holtås S., Isberg B., et al. Tolerance and efficiency of omniscan in MR imaging of the central nervous system. Acta Radiology 1996, 37:223-228.
35. Kirchin M., Pirovana G., Ventianer C., Spinazzi A. Safety assessment of gadovenate dimeglumine (Multihance): extended clinical experience from phase 1 studies to post marketing surveillance. Journal of Magnetic Resonance Imaging 2001, 14:281-294.
36. Brown J., Kristy R., Stevens G., Pierro J. The OptiMARK clinical development program; summary of safety data. British Journal of Magnetic Imaging 2002, 15:445-446.
37. Department of Health Patient Group Directions: Summary of Product Characteristics, last updated, [accessed 16.12.09.]. http://www.dh.gov.uk/PolicyAndGuidance/EmergencyPlanning/EmergencyPreparednessArticle/fs/en%3fCONTENTID=4069610&chk=in7ZEF.
38. College of Radiographers Prescribing by radiographers: a vision paper 2001, College of Radiographers, London.
39. Department of Health Final report on prescribing, supply and administration of medicines 1999, Department of Health, London, [Last accessed 16/12/09].
40. College of Radiographers The scope of practice 2003, College of Radiographers, London.
41. Steen H., Schwenger V. Good MRI images: to Gad or not to Gad?. Paediatric Nephrology 2007, 22:1239-1242. Skills for Health website:. http://www.skillsforhealth.org.uk/standards_database/index.htm.
42. Health Professions Council Standards of proficiency radiographers 2003, HPC, London.
43. Briaco S. Health and safety in at work-practical perspective for radiographers and technologists. Workplace safety in radiological environment. Pre conference session European Congress of Radiology Vienna 2007.
44. Bailey W., Marshall G., Coals J. A pilot study to investigate the effect of a hydration regime upon immediate and 24h delayed MRI contrast agent reactions. Radiography 2007, 13(1):e90-e98.
45. Thomsen H. Guidelines for contrast media from the European Society of Urogenital Radiology guidelines. American Journal of Roentgenology 2003, 18:1463-1471.
46. Thomsen H., Morcos S. Contrast media and the kidney: European Society of Urogenital Radiology guidelines. British Journal of Radiology 2003, 76:513-518.
47. Niendorf H., Dinger J., Haustein J., Cornelius I., Alhassan A., Clauss W. Tolerance data of Gd-DTPA: a review. European Journal of Radiology 1991, 13:15-20.
48. Murphy K., Brunberg J., Cohan R. Adverse reactions to gadolinium contrast media: a review of 36 cases. American Journal of Roentgenology 1996, 167:847-849.
49. Newman-Sander T. Association notices: serious untoward incident 2006, MRRA, UK, Magnetic Resonance Radiology Association.
50. Sahni H., Jayakumar P.N., Lalla R.K., Vasudev M.K., Kavoor J.M.E. Anaphylactoid reaction following intravenous gadolinium dimeglumine-a case report. India Journal of Radiological Imaging 2002, 12(1):81-82.
51. Goldstein H., Kashanian F., Blumetti R., Holyoak W., Hugo F., Blumenfield D. Safety assessment of Gd-DTPA in U.S. clinical trials. Radiology 1990, 174:17-23.
52. Abuhdah H., Kosaraju V., Kaewlai R. Acute adverse reactions to gadopentetate and gadobenate dimeglumine: experience with 32,659 injections. American Journalism Review 2010, 194:430-434.
53. Giacometti A., Joseph G., Peterson J., Davis P. Comparison of full- and half-dose gadolinium-DTPA: MR imaging of the normal sella. American Journal of Neuroradiology 1993, 14:123-127.
54. Unterweger M., Froehlich J., Kubik-Huch R., Seifert B., Birrer M., Huber T., et al. Dose optimization of contrast-enhanced carotid MR angiography. European Radiology 2005, 15:1797-1805.
55. Curker T., Lee J.H., Bangerter N.K., Hargreaves B.A., Nishimura D.G. Non-contrast-enhanced flow-independent peripheral MR angiography with balanced SSFP. Magnetic Resonance Medicine 2009, 61(6):1533-1539.